GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Synthaverse SVE.WA · PLN

Health Care · GPW · 🇵🇱 Poland

Compare

2.58

-0.39%

Close of 9 Nov 2026, in PLN

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Synthaverse

Its shares trade on GPW under the ticker SVE.WA. It has been listed since 29 July 2011. In the fiscal year to 31 December 2025, it reported revenue of PLN 42.0m and a net loss of PLN 19.9m. At that date it held total assets of PLN 304.1m and shareholders' equity of PLN 124.7m.

Biomed Lublin Wytwornia Surowic i Szczepionek SA engages in the manufacture of pharmaceutical products. The company is headquartered in Lublin, Woj. Lubelskie. The company went IPO on 2011-07-29.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
29 Jul 2011
Employees
224

Leadership

Pay as last reported

  • Mr. Jaroslaw BlaszczakChairman of the Supervisory Board, since 2016PLN 68,000
  • Mieczyslaw StarkowiczPresident of the Management Board
  • Mr. Wiktor NapioraVice Chairman of the Supervisory Board, since 2016PLN 93,000
  • Mr. Artur ChodkowskiVice President of the Management Board
  • Ms. Katarzyna KrukowskaChief Accounting Officer
  • Mr. Piotr FicMember of the Management Board
  • Mr. Jakub WinklerMember of the Management Board
  • Mr. Waldemar SierockiSecretary of the Supervisory BoardPLN 1,000
  • Mr. Konrad MiterskiIndependent Member of the Supervisory BoardPLN 1,000
  • Dr. Dirk PamperinIndependent Member of the Supervisory Board
  • Mr. Dariusz KucowiczMember of the Supervisory BoardPLN 232,000
  • Mr. Piotr KwasniewskiMember of the Supervisory BoardPLN 1,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Biomed Lublin Wytwornia Surowic i Szczepionek SA has several strengths that contribute to its strong position in the market:

Weaknesses

  • Despite its strengths, Biomed Lublin Wytwornia Surowic i Szczepionek SA faces certain weaknesses that may hinder its growth:

Opportunities

  • Biomed Lublin Wytwornia Surowic i Szczepionek SA can leverage the following opportunities to expand its market reach:

Threats

  • Biomed Lublin Wytwornia Surowic i Szczepionek SA should be cautious of the following threats in the competitive market:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.